Skip to main navigation Skip to search Skip to main content

A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers

Project: Research

Project Details

StatusFinished
Effective start/end date07/19/23 → 06/6/25

Funding

  • AstraZeneca Pharmaceuticals LP: $30,262.00